CLAIM CARD
Mechanistically, the anti-inflammatory properties of colchicine — primarily through tubulin binding and neutrophil activation suppression — provide a plausible substrate for the cardiovascular benefits observed in the meta-analytic synthesis of Li 2025. Pan 2023 demonstrated that peri-operative low-dose colchicine (0.5 mg daily) modulated inflammatory pathways in the surgical context, with significant reductions in key biomarkers (P < 0.01). Preclinical data and the long-term safety observations from Broekhoven 2022 suggest that sustained low-dose exposure does not adversely affect major organ function, supporting the tolerability of extended regimens. Samuel 2020 contextualized these pharmacokinetic and efficacy profiles within a health-economic framework using COLCOT trial data.
Evidence grade: exploratory
Contradiction status: none
Publication: 873ff54a-3a1e-4c35-b4ff-b2bb5ab68649
Provenance: Derivation Web chain
Citation Support
source_1Mohammadnia 2025source_2Li 2025source_3Ammirati 2026source_4Pascart 2026source_5Broekhoven 2022